Tabulated list of adverse reactions: The following undesirable effects have been observed during clinical trials and/or post-marketing use with perindopril or amlodipine given separately and ranked under the MedDRA classification by body system and under the following frequency: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). (See Tables A and B.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/imageAdditional information concerning amlodipine: Exceptional cases of extrapyramidal syndrome have been reported with calcium inhibitor treatment.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
View ADR Reporting Link
Sign Out